Table 1 Patient characteristics of the entire trial cohort and those stratified by CT CAD categories
Variables | Total cohort | No CAD | Nonobstructive CAD | Obstructive CAD | p value |
|---|---|---|---|---|---|
n = 841 | n = 485 | n = 192 | n = 164 | n = 841 | |
Age (years) | 69.5 ± 5.8 | 68.4 ± 5.5 | 70.6 ± 6.3 | 71.3 ± 5.4 | < 0.001 |
Male | 627 (74.6) | 334 (68.9) | 155 (80.7) | 138 (84.1) | < 0.001 |
Suspected CAD | 70 (8.3) | 28 (5.8) | 15 (7.8) | 27 (16.5) | 0.001 |
Positive ECG | 110 (13.1) | 48 (10.0) | 17 (8.9) | 45 (27.4) | < 0.001 |
HR (beats/min) | 73.6 ± 25.7 | 74.0 ± 30.9 | 72.8 ± 17.2 | 73.3 ± 13.8 | 0.855 |
LVEF (%) | 66.6 ± 7.1 | 66.5 ± 6.7 | 67.0 ± 6.9 | 66.4 ± 8.3 | 0.655 |
Median Agatston score†|  | 0 | 71 (17.4, 190.2) | 348.4 (124.3, 789.9) | < 0.001 |
Risk factors | |||||
 Smoking | 401 (47.7) | 210 (43.3) | 100 (52.1) | 91 (55.5) | 0.003 |
 Diabetes mellitus | 85 (10.1) | 38 (7.8) | 21 (10.9) | 26 (15.9) | 0.004 |
 Hypertension | 293 (34.8) | 138 (28.5) | 73 (38.0) | 82 (50.0) | < 0.001 |
 Hyperlipidemia | 248 (29.5) | 137 (28.2) | 57 (29.7) | 54 (32.9) | 0.272 |
 Stroke | 26 (3.1) | 12 (2.5) | 5 (2.6) | 9 (5.5) | 0.101 |
Medication use at perioperative period | |||||
 Statins | 80 (9.5) | 16 (3.3) | 11 (5.7) | 53(32.3) | < 0.001 |
 ACEi or ARB | 66 (7.8) | 27 (5.6) | 17 (8.9) | 22 (13.4) | 0.001 |
Calcium channel blockers | 195 (23.2) | 91 (18.8) | 52 (27.1) | 52 (31.7) | < 0.001 |
 Beta-blocker | 124 (14.7) | 53 (10.9) | 26 (13.5) | 45 (27.4) | < 0.001 |
 Diuretics | 288 (34.2) | 148 (30.5) | 81 (42.2) | 59 (36.0) | 0.06 |
 Nitrate agent | 184 (21.9) | 86 (17.7) | 45 (23.4) | 53 (32.3) | < 0.001 |